Simulations Plus Reports Third Quarter FY2018 Financial Results

Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling
and simulation solutions for the pharmaceutical, biotechnology,
chemicals, and consumer goods industries, today reported financial
results for its third quarter of fiscal year 2018 (3QFY18) and the first
nine months of fiscal year 2018 (9moFY18), the period ended May 31, 2018.

3QFY18 highlights compared with 3QFY17:

9moFY18 highlights compared with 9moFY17:

Walt Woltosz, chairman of the board of Simulations Plus, said:
“Simulations Plus continues to execute on its growth strategy and
deliver quantifiable value to its expanding customer base. With more
than a decade of consistent growth in revenue and earnings, we believe
we are well-positioned for continued success, especially as in silico
modeling takes on an increasing importance with our customers. We
believe simulation and modeling, and consulting services based on them,
are essential components of reducing the cost and time required for drug
discovery and development. I believe it is an appropriate time for me to
turn over the day-to-day leadership of our strong organization to Shawn
O’Connor, our experienced new CEO.”

John Kneisel, chief financial officer of Simulations Plus, added: “We
continue to deliver consistent growth and profitability, and maintain a
strong cash position. Consolidated cash as of May 31, 2018, was $7.2
million, and $9.9 million as of July 9, 2018. Our financial position has
allowed us to make strategic investments over the last several years and
enabled continued investment in research and development to bolster our
strategic position in the market. This year we have released new
versions of GastroPlus™,
Predictor™, PKPlus™,
and are working on NAFLDsym™.
As the recognized leader in the space, with a growing base of loyal
customers, these product introductions will help us capture market share
and better serve the industry.”

Quarterly Dividend Declared

The Company’s Board of Directors has declared a cash dividend of $0.06
per share of the Company’s common stock payable on August 2, 2018, to
shareholders of record as of July 26, 2018. The declaration of any
future dividends will be determined by the Board of Directors each
quarter and will depend on earnings, financial condition, capital
requirements, and other factors.

Investor Conference Call

The Company invites all interested persons to attend its conference call
at 4:15 p.m. Eastern Time on July 10, 2018. The live
webcast/teleconference will be accessible by registering here.
Please dial in five to ten minutes prior to the scheduled start time. A
live, listen-only webcast will also be available by dialing (914)
614-3221, and entering access code 637-051-430. A replay of the webcast
will be available at the Investors
section of the Simulations Plus website following the call.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of drug discovery and
development software as well as a leading provider of both preclinical
and clinical pharmacometric consulting
services for regulatory submissions and quantitative systems
pharmacology/toxicology models for drug-induced
liver injury and nonalcoholic
fatty liver disease. The company is a global leader focused on
improving the ways scientists use knowledge and data to predict the
properties and outcomes of pharmaceutical, biotechnology, and chemical
agents. Our software is licensed to and used in the conduct of research
by major pharmaceutical, biotechnology, chemical, consumer goods
companies, and regulatory agencies worldwide. Our innovations in
integrating new and existing science in medicinal chemistry,
computational chemistry, artificial intelligence, pharmaceutical
science, biology, and physiology into our software have made us the
leading software provider for molecular property prediction from
structure and physiologically
based pharmacokinetic modeling and simulation. For more information,
visit our website at

Safe Harbor Statement Under the Private Securities Litigation Reform
Act of 1995 – With the exception of historical information, the
matters discussed in this press release are forward-looking statements
that involve a number of risks and uncertainties. Words like “believe,”
“expect” and “anticipate” mean that these are our best estimates as of
this writing, but that there can be no assurances that expected or
anticipated results or events will actually take place, so our actual
future results could differ significantly from those statements. Factors
that could cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the pharmaceutical
industry, our ability to finance growth, our ability to continue to
attract and retain highly qualified technical staff, our ability to
identify and close acquisitions on terms favorable to the Company, and a
sustainable market. Further information on our risk factors is contained
in our quarterly and annual reports and filed with the U.S. Securities
and Exchange Commission.

Follow us on Twitter
| LinkedIn



As of



For the three and nine months ended May 31, 2018 and May 31,

Gain (loss) on currency exchange

View source version on

Leave a Comment